Ann Rheum Dis 2001;60:577-584 ( June )

Extended report

Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease M Binks, J R Passweg, D Furst, P McSweeney, K Sullivan, C Besenthal, J Finke, H H Peter, J van Laar, F C Breedveld, W E Fibbe, D Farge, E Gluckman, F Locatelli, A Martini, F van den Hoogen, L van de Putte, A V N Schattenberg, R Arnold, P A Bacon, P Emery, I Espigado, B Hertenstein, F Hiepe, A Kashyap, I Kötter, A Marmont, A Martinez, M J Pascual, A Gratwohl, H G Prentice, C Black, A Tyndall

Correspondence to: Professor A Tyndall, Chairman, EBMT/EULAR Working Party on Autoimmune Diseases, University Department of Rheumatology, Felix Platter Hospital, Burgfelderstrasse 101, CH-4012 Basel, Switzerland alan.tyndall{at}fps-basel.ch

Accepted for publication 6 March 2001

BACKGROUNDSystemic sclerosis (SSc, scleroderma) in either its diffuse or limited skin forms has a high mortality when vital organs are affected. No treatment has been shown to influence the outcome or significantly affect the skin score, though many forms of immunosuppression have been tried. Recent developments in haemopoietic stem cell transplantation (HSCT) have allowed the application of profound immunosuppression followed by HSCT, or rescue, to autoimmune diseases such as SSc.
METHODSResults for 41 patients included in continuing multicentre open phase I/II studies using HSCT in the treatment of poor prognosis SSc are reported. Thirty seven patients had a predominantly diffuse skin form of the disease and four the limited form, with some clinical overlap. Median age was 41 years with a 5:1 female to male ratio. The skin score was >50% of maximum in 20/33 (61%) patients, with some lung disease attributable to SSc in 28/37 (76%), the forced vital capacity being <70% of the predicted value in 18/36 (50%). Pulmonary hypertension was described in 7/37 (19%) patients and renal disease in 5/37 (14%). The Scl-70 antibody was positive in 18/32 (56%) and the anticentromere antibody in 10% of evaluable patients. Peripheral blood stem cell mobilisation was performed with cyclophosphamide or granulocyte colony stimulating factor, alone or in combination. Thirty eight patients had ex vivo CD34 stem cell selection, with additional T cell depletion in seven. Seven conditioning regimens were used, but six of these used haemoimmunoablative doses of cyclophosphamide +/- anti-thymocyte globulin +/- total body irradiation. The median duration of follow up was 12 months (3-55).
RESULTSAn improvement in skin score of >25% after transplantation occurred in 20/29 (69%) evaluable patients, and deterioration in 2/29 (7%). Lung function did not change significantly after transplantation. One of five renal cases deteriorated but with no new occurrences of renal disease after HSCT, and the pulmonary hypertension did not progress in the evaluable cases. Disease progression was seen in 7/37 (19%) patients after HSCT with a median period of 67 (range 49-255) days. Eleven (27%) patients had died at census and seven (17%) deaths were considered to be related to the procedure (direct organ toxicity in four, haemorrhage in two, and infection/neutropenic fever in one). The cumulative probability of survival at one year was 73% (95% CI 58 to 88) by Kaplan-Meier analysis.
CONCLUSIONDespite a higher procedure related mortality rate from HSCT in SSc compared with patients with breast cancer and non-Hodgkin's lymphoma, the marked impact on skin score, a surrogate marker of mortality, the trend towards stabilisation of lung involvement, and lack of other treatment alternatives justify further carefully designed studies. If future trials incorporate inclusion and exclusion criteria based on this preliminary experience, the predicted procedure related mortality should be around 10%.

---

© 2001 by Annals of the Rheumatic Diseases
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Stem cell transplantation: limits and hopes

K P MACHOLD and J S SMOLEN
Ann Rheum Dis 2001 60: 548-549. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Hanitsch, L. G., Burmester, G.-R., Witt, C., Hunzelmann, N., Genth, E., Krieg, T., Lehmacher, W., Melchers, I., Meurer, M., Muller-Ladner, U., Schulze-Lohoff, E., Becker, M., Sunderkoetter, C., the DNSS centers, , Riemekasten, G. (2009). Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. Rheumatology (Oxford) 48: 70-73 [Abstract] [Full Text]  
• van Laar, J M, Farge, D, Tyndall, A (2008). Stem cell transplantation: a treatment option for severe systemic sclerosis?. Ann Rheum Dis 67: iii35-iii38 [Abstract] [Full Text]  
• Braiteh, F., Hymes, S. R., Giralt, S. A., Jones, R. (2008). Complete Remission of Psoriasis After Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma. JCO 26: 4511-4513 [Full Text]  
• Tehlirian, C V, Hummers, L K, White, B, Brodsky, R A, Wigley, F M (2008). High-dose cyclophosphamide without stem cell rescue in scleroderma. Ann Rheum Dis 67: 775-781 [Abstract] [Full Text]  
• Burt, R. K., Loh, Y., Pearce, W., Beohar, N., Barr, W. G., Craig, R., Wen, Y., Rapp, J. A., Kessler, J. (2008). Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases. JAMA 299: 925-936 [Abstract] [Full Text]  
• Cassinotti, A, Annaloro, C, Ardizzone, S, Onida, F, Volpe, A D., Clerici, M, Usardi, P, Greco, S, Maconi, G, Porro, G B., Deliliers, G L. (2008). Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut 57: 211-217 [Abstract] [Full Text]  
• Vonk, M C, Marjanovic, Z, van den Hoogen, F H J, Zohar, S, Schattenberg, A V M B, Fibbe, W E, Larghero, J, Gluckman, E, Preijers, F W M B, van Dijk, A P J, Bax, J J, Roblot, P, van Riel, P L C M, van Laar, J M, Farge, D (2008). Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 67: 98-104 [Abstract] [Full Text]  
• van Laar, J. M., Tyndall, A. (2006). Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 45: 1187-1193 [Abstract] [Full Text]  
• Tsukamoto, H, Nagafuji, K, Horiuchi, T, Miyamoto, T, Aoki, K, Takase, K, Henzan, H, Himeji, D, Koyama, T, Miyake, K, Inoue, Y, Nakashima, H, Otsuka, T, Tanaka, Y, Nagasawa, K, Harada, M (2006). A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis 65: 508-514 [Abstract] [Full Text]  
• Bohgaki, T, Amasaki, Y, Nishimura, N, Bohgaki, M, Yamashita, Y, Nishio, M, Sawada, K-i, Jodo, S, Atsumi, T, Koike, T (2005). Up regulated expression of tumour necrosis factor {alpha} converting enzyme in peripheral monocytes of patients with early systemic sclerosis. Ann Rheum Dis 64: 1165-1173 [Abstract] [Full Text]  
• Trad, S., Amoura, Z., Haroche, J., Huong Du Boutin, L. T., Wechsler, B., Leblond, V., Piette, J.-C. (2005). Fatal progressive systemic sclerosis following autologous stem cell transplantation and high-dose chemotherapy. Rheumatology (Oxford) 44: 951-953 [Full Text]  
• Farge, D, Passweg, J, van Laar, J M, Marjanovic, Z, Besenthal, C, Finke, J, Peter, H H, Breedveld, F C, Fibbe, W E, Black, C, Denton, C, Koetter, I, Locatelli, F, Martini, A, Schattenberg, A V N, van den Hoogen, F, van de Putte, L, Lanza, F, Arnold, R, Bacon, P A, Bingham, S, Ciceri, F, Didier, B, Diez-Martin, J L, Emery, P, Feremans, W, Hertenstein, B, Hiepe, F, Luosujarvi, R, Leon Lara, A, Marmont, A, Martinez, A M, Pascual Cascon, H, Bocelli-Tyndall, C, Gluckman, E, Gratwohl, A, Tyndall, A (2004). Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 63: 974-981 [Abstract] [Full Text]  
• Storb, R. F., Lucarelli, G., McSweeney, P. A., Childs, R. W. (2003). Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors. ASH Education Book 2003: 372-397 [Abstract] [Full Text]  
• Huhn, R. D., Fogarty, P. F., Nakamura, R., Read, E. J., Leitman, S. F., Rick, M. E., Kimball, J., Greene, A., Hansmann, K., Gratwohl, A., Young, N., Barrett, A. J., Dunbar, C. E. (2003). High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 101: 71-77 [Abstract] [Full Text]  
• McSweeney, P. A., Nash, R. A., Sullivan, K. M., Storek, J., Crofford, L. J., Dansey, R., Mayes, M. D., McDonagh, K. T., Nelson, J. L., Gooley, T. A., Holmberg, L. A., Chen, C. S., Wener, M. H., Ryan, K., Sunderhaus, J., Russell, K., Rambharose, J., Storb, R., Furst, D. E. (2002). High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 100: 1602-1610 [Abstract] [Full Text]  
• Burt, R. K., Slavin, S., Burns, W. H., Marmont, A. M. (2002). Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?. Blood 99: 768-784 [Abstract] [Full Text]  
• Marmont, A M (2001). Lupus: tinkering with haematopoietic stem cells. Lupus 10: 769-774  
• Tyndall, A, Passweg, J, Gratwohl, A (2001). Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann Rheum Dis 60: 702-707 [Abstract] [Full Text]